- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01912391
Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder
A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Borderline Personality Disorder (BPD) is a chronic disorder occurring in 2-3% of the population. BPD is accompanied by high levels of co-existing psychiatric and physical disorders. One key predictor is persistent and recurring major depressive disorder.
Since BPD is most closely linked with mood disorders and depression in particular, the use of antidepressant medications to treat the disorder is logical. However, to date, there are no FDA approved treatments for BPD. The American Psychiatric Association's Treatment Guidelines for Borderline Personality Disorder recommend antidepressants as a primary treatment of the disorder.
Earlier trials using antidepressants that increase certain brain chemicals, such as, serotonin and noradrenalin have shown efficacy in controlling the mood swings of the illness for many people. These studies also document efficacy in controlling physical disorders, including headaches, migraines, irritable bowel, neurodermatitis (skin rash), fibromyalgia, premenstrual syndrome, and tempomandibular joint dysfunction (TMJ).
group of antidepressants known as monoamine oxidase inhibitors (MAOIs) have also been shown to be effective in BPD patients. The oral form of these medications was accompanied by dietary restrictions, potential drug interactions, blood pressure changes and weight gain.
Selegiline, a MAOI antidepressant, was put into a skin patch delivery system (transdermal) that reduced the side-effect profile. Trials without placebo control showed many individuals with BPD benefit from the selegiline skin patch. This trial will look at individuals on the selegiline and placebo to make sure the selegiline is or is not effective in treating BPD.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Fresno, California, United States, 93720
- Mood and Anxiety Research, Inc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has primary diagnosis of Borderline Personality Disorder(BPD).
- Subject has Symptomatology of BPD for at least 1 year.
- Subject understands the study procedures and voluntarily agree to participate.
- Subject is able to read, understand and complete questionnaires.
- Subject agrees to use (2)acceptable forms of contraception throughout the study.
- Patient must have a screening SCL 90-R score of > 120 (range 0-360).
Exclusion Criteria:
- Subject is not pregnant or breast feeding.
- Subject is unlikely to adhere to the study procedures and restrictions.
- Patient has failed treatment due to lack of efficacy of monoamine oxidase inhibitor(MAOI) medication.
- Patient anticipates need for surgery during the study.
- Patient has another predominant personality disorder other than BPD.
- Subject has an active history of substance abuse or dependence, e.g.,Positive Drug screen
- Subject has other health issues which could interfere with study interpretation.
- Subject reports recent suicide attempts or homicide attempts in the past 3 months.
- Subject must be substance abuse or dependence clean for (1) year.
- Subject has a history of a primary malignancy < 5 yrs.
- Subject has a medical condition(s)that are excluded, per Protocol, or are unstable.
- Subject has abnormal screening laboratory values, per Protocol, or other clinically significant, unexplained laboratory abnormality.
- Subject is currently participating or has participated in a study within 30 days.
- Patient has donated blood products or has had phlebotomy of > 300 ml within 8 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Selegiline
Transdermal Selegiline 12 mg patch Apply (1) patch daily
|
The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
Other Names:
|
Placebo Comparator: Placebo (for Selegiline)
Transdermal Placebo patch Apply (1) patch daily
|
Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg.
patch
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Efficacy Measurement: Changes in the Hopkins Symptom Checklist 90-Revised (SCL 90-R) scale
Time Frame: Weeks 1-12
|
The study subject will complete the SCL 90-R questionnaire at each visit on arrival at the office prior to meeting with the research staff.
This will serve as the primary efficacy measure of outcome for the study.
This instrument has been utilized in clinical trials since the early 1960s, and has a good ability to measure overall levels of psychological and physical functioning in this patient group.
|
Weeks 1-12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Efficacy Measurement: Change in Hamilton Depression Inventory 17 Questions (HAM-D)
Time Frame: Weeks 1 - 12
|
Clinician will administer the HAM-D scale to subject at each visit to assess any changes in their overall symptoms, functioning social and daily life.
|
Weeks 1 - 12
|
Clinical Global Impression of Change- Clinician (CGIc)
Time Frame: Weeks 3-12
|
Clinician will assess any improvement in their overall symptoms, functioning social and daily life beginning at week 3(Visit 3)through week 12 (Visit 6).
|
Weeks 3-12
|
Clinical Global Impression Change- Patient (CGIp)
Time Frame: Weeks 3 -12
|
Patient will assess any improvement in their overall symptoms, functioning social and daily life beginning at week 3(Visit 3)through week 12 (Visit 6).
|
Weeks 3 -12
|
Sheehan Disability Scale (SDS)
Time Frame: Weeks 1, 4, 12
|
Patient will assess any improvement in their overall functioning in their work / school, social and daily life at 3 time points
|
Weeks 1, 4, 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical and Laboratory Measurements for Safety: Change in Columbia Suicide Severity Rating Scale (CSSRS); Adverse Events; Vitals Signs; Body Weight; Laboratory Values; Blood Pressure; Study Drug Compliance; Concomitant Medication Compliance
Time Frame: Treatment Phase (1-12 weeks)
|
Study subjects will be monitored for safety throughout the study beginning at the Screening Visit (V1).
At each visit, subjects will have various clinical, laboratory and safety measurements conducted.
Results will be assessed by the clinical team and will be monitored, at each visit, until the term of their participation.
A 2 week, post-study, follow-up will be conducted by the study staff.
|
Treatment Phase (1-12 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Paul J Markovitz, MD, PhD, Mood and Anxiety Research, Inc
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Personality Disorders
- Borderline Personality Disorder
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Neuroprotective Agents
- Protective Agents
- Psychotropic Drugs
- Antidepressive Agents
- Monoamine Oxidase Inhibitors
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Selegiline
Other Study ID Numbers
- PJM-01
- WV26504-4245 (Other Grant/Funding Number: WV26504-4245)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Borderline Personality Disorder
-
University Hospital, Basel, SwitzerlandLeading House for the Latin American Region (Seed Money Grant SMG 1730)WithdrawnBorderline Personality Disorder (BPD)
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
University of EdinburghRecruitingEmotionally Unstable Personality Disorder, Borderline TypeUnited Kingdom
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownBorderline Personality Disorder.Spain
-
Silvia Elisa Hurtado SantiagoCompletedPersonality Disorder, BorderlineSpain
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
Universitat Jaume IHospital de la RiberaRecruitingBorderline Personality Disorder (BPD)Spain
-
University of OldenburgProf. René Hurlemann; Jella Voelter, M.Sc.RecruitingBorderline Personality Disorder (BPD)Germany
-
NHS Greater Glasgow and ClydeUnknownBorderline Personality Disorder (BPD) | Antisocial Personality Disorder (ASPD)United Kingdom
-
Rutgers, The State University of New JerseyActive, not recruitingBorderline Personality Disorder in AdolescenceUnited States
Clinical Trials on Selegiline
-
National Institute on Drug Abuse (NIDA)CompletedMarijuana AbuseUnited States
-
Somerset PharmaceuticalsCompleted
-
Somerset PharmaceuticalsCompleted
-
National Institute of Allergy and Infectious Diseases...National Institute of Neurological Disorders and Stroke (NINDS); Neurologic...CompletedHIV Infections | Cognition DisordersUnited States
-
Ludwig-Maximilians - University of MunichCompletedMénière's DiseaseGermany
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Cognitive DisordersUnited States
-
New York State Psychiatric InstituteTerminated
-
Parkinson's Disease and Movement Disorder Center...Bausch Health Americas, Inc.CompletedParkinson's DiseaseUnited States
-
Somerset PharmaceuticalsCompletedMajor DepressionUnited States